Kairos Pharma Ltd. (NYSE American: KAPA) announced that its President and Chief Scientific Officer, Neil Bhowmick, will present and moderate a discussion at the 24th Annual Discovery on Target Drug Discovery Conference, held from September 28 to October 1 in Boston. The conference is a key event for professionals in drug discovery and development, and Kairos Pharma's participation underscores its commitment to advancing oncology therapeutics.
Bhowmick will moderate a breakout session on September 30 titled “Winning the Race against Cancer Therapy Resistance.” This session will focus on Kairos Pharma's strategy of targeting cancer drug resistance to extend the efficacy of previously effective drug candidates. The approach is critical as resistance to cancer therapies remains a major challenge in treating solid tumors, often leading to relapse and limited treatment options.
In addition, Bhowmick will deliver an oral plenary presentation on September 30 at 2:35 p.m. Eastern, detailing the company's drug candidate KROS-101. The presentation will highlight KROS-101's targeting of GITR (Glucocorticoid-Induced TNF Receptor) to increase T-cell function and expand effector T-cells with anti-tumor activity. This mechanism represents a promising avenue for enhancing immune response against solid tumors, which could potentially improve outcomes for patients who have not responded to existing therapies.
Kairos Pharma, based in Los Angeles, California, is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Its lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. This dual approach of targeting both GITR and CD105 could position Kairos Pharma as a significant player in the immuno-oncology space.
For investors and industry observers, Kairos Pharma's presentation at the Discovery on Target Conference could signal progress in its pipeline and potentially attract partnership or investment interest. The conference provides a platform for the company to showcase its science to a global audience of researchers, clinicians, and pharmaceutical executives. As cancer therapy resistance continues to be a major hurdle, innovative strategies like those from Kairos Pharma are closely watched for their potential to transform treatment paradigms.
To view the full press release, visit https://nnw.fm/DoHxL. The latest news and updates relating to KAPA are available in the company’s newsroom at https://nnw.fm/KAPA. NetworkNewsWire, a specialized communications platform, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, delivering access to a vast network of wire solutions via InvestorWire and more. For full terms of use and disclaimers, see https://www.NetworkNewsWire.com/Disclaimer.
